C.R. Bard, Inc. (NYSE:BCR) VP Betty D. Larson sold 5,906 shares of the firm’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $330.16, for a total value of $1,949,924.96. Following the completion of the sale, the vice president now directly owns 10,753 shares in the company, valued at approximately $3,550,210.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of C.R. Bard, Inc. (BCR) traded down $3.39 during midday trading on Friday, hitting $331.89. The stock had a trading volume of 672,600 shares, compared to its average volume of 670,174. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $335.84. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. The stock has a market cap of $23,950.00, a P/E ratio of 28.95, a PEG ratio of 2.56 and a beta of 0.53.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The business had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. During the same quarter in the prior year, the business earned $2.64 earnings per share. C.R. Bard’s revenue for the quarter was up 5.1% on a year-over-year basis. research analysts expect that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a dividend of $0.26 per share. The ex-dividend date is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s payout ratio is 13.70%.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/insider-selling-c-r-bard-inc-bcr-vp-sells-1949924-96-in-stock.html.
Several research analysts recently issued reports on BCR shares. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. BidaskClub lowered C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Finally, Cowen and Company reissued a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a strong buy rating to the stock. C.R. Bard currently has a consensus rating of “Hold” and a consensus target price of $303.50.
A number of hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN raised its holdings in C.R. Bard by 32.8% during the 3rd quarter. Wells Fargo & Company MN now owns 775,683 shares of the medical instruments supplier’s stock valued at $248,607,000 after acquiring an additional 191,443 shares during the period. Zeke Capital Advisors LLC bought a new stake in C.R. Bard during the 3rd quarter valued at $339,000. Amalgamated Bank raised its holdings in C.R. Bard by 2.2% during the 3rd quarter. Amalgamated Bank now owns 8,744 shares of the medical instruments supplier’s stock valued at $2,802,000 after acquiring an additional 189 shares during the period. Nuance Investments LLC raised its holdings in C.R. Bard by 47.6% during the 3rd quarter. Nuance Investments LLC now owns 479,686 shares of the medical instruments supplier’s stock valued at $153,739,000 after acquiring an additional 154,650 shares during the period. Finally, Iberiabank Corp raised its holdings in C.R. Bard by 31.8% during the 3rd quarter. Iberiabank Corp now owns 4,578 shares of the medical instruments supplier’s stock valued at $1,467,000 after acquiring an additional 1,104 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.